Physician profile
Heidi E Kile
NPI 1245316470
$2,730.17
in general payments reported to CMS, 2019-2025
23 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $824 · 2022: $704 · 2023: $468 · 2024: $278 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $564.58 | 2021-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $361.48 | 2021-2025 | |
| Amgen INC. | $250.15 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.77 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $174.13 | 2024-2025 | Wegovy |
| Boston Scientific Corporation | $154.66 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.13 | 2022 | |
| Alexion Pharmaceuticals, INC. | $97.14 | 2021 | |
| Impulse Dynamics (USA) INC. | $96.51 | 2023-2024 | Optimizer, Optimizer |
| Coloplast Corp | $72.78 | 2023 | Titan |
| Abbott Laboratories | $72.59 | 2024-2025 | Amplatzer Amulet, Cardiomems |
| Actelion Pharmaceuticals US, INC. | $70.16 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.44 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $66.42 | 2021-2022 | |
| Abbvie INC. | $63.32 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $44.16 | 2022-2025 | Camzyos |
| Edwards Lifesciences Corporation | $39.78 | 2021 | |
| Medtronic, INC. | $39.77 | 2021-2025 | Corevalve Evolut R |
| Regeneron Healthcare Solutions, INC. | $29.73 | 2023 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $29.23 | 2021 | |
| Esperion Therapeutics, INC. | $27.41 | 2022 | |
| Scpharmaceuticals INC. | $16.72 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Kile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.